A GSK lab in London.
Oli Scarff | Getty Photographs
Britain’s GlaxoSmithKline and German biotech agency CureVac struck a 150 million euro ($180 million) deal to develop next-generation vaccines towards Covid-19 that focus on a number of variants in a single product.
In a joint assertion on Wednesday, the companions stated they had been focusing on a doable launch in 2022.
GSK, which holds a stake in CureVac, may even help the manufacturing of as much as 100 million doses of CureVac’s first technology Covid-19 vaccine candidate in 2021, they stated.
For GSK, the world’s largest vaccine maker by gross sales, it marks a recent try and play a related function in preventing the pandemic after a Covid-19 alliance with Sanofi was hobbled by improvement delays and after an analogous collaboration with China’s Clover Biopharmaceuticals was ended.